CCL18 and neoplasm: Consistent with our previous findings [15], the number of CCL18+ TAMs increased with higher tumor burden as defined by tumor size (p < 0.001) and staging (p = 0.014), as well as with aggressive tumor biology defined by advanced histological grading (p = 0.035), lymph node metastasis (p < 0.001), and distant metastasis (p = 0.018).